Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LIPC | P11150 | 1/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043841 | 0.89 | MEN1 (0.47) | PLK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL686659 | 0.86 | CCR2 (0.51) | PLK1MEN1KMT2AGAACCR2 | |
| SCHEMBL3897253 | 0.85 | PLK1 (0.50) | PLK1MEN1KMT2AKDM4ELIPC | |
| SCHEMBL14014908 | 0.84 | MEN1 (0.50) | MEN1KMT2AMAPTGAACCR2 | |
| SCHEMBL5127442 | 0.84 | LIPC (0.53) | PLK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3894930 | 0.82 | LIPC (0.66) | PLK1KDM4EMAPTLIPCLIPG | |
| SCHEMBL2081759 | 0.81 | GAA (0.45) | PLK1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL3885198 | 0.81 | KDM4E (0.59) | PLK1KDM4ELIPCLIPGGRIK1 | |
| SCHEMBL2080677 | 0.81 | CCR2 (0.50) | PLK1MEN1KMT2AKDM4ELIPC | |
| SCHEMBL13754378 | 0.80 | GRIK1 (0.55) | MEN1KMT2AKDM4EMAPTGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1667966-B1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7863333-B2 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863317-B2 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1667966-A4 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7449493-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMACEUTICAL COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1660445-A4 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021498-A1 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021499-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | PLK1 4773/4885MEN1 3483/4885KMT2A 4093/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | PLK1 4662/4885MEN1 2257/4885KMT2A 3842/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | PLK1 4371/4885MEN1 3015/4885KMT2A 4491/4885 |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | PLK1 4854/4885MEN1 1428/4885KMT2A 3716/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | PLK1 4371/4885MEN1 3015/4885KMT2A 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.